DiaMedica Therapeutics (DMAC) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 52.3% versus a gain of 16.5%. Over five years, DMAC leads with a +94.9% price change compared with -67.4% for TECX. Tectonic Therapeutic is the larger company by market cap ($444.0 million vs $430.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | TECX |
|---|---|---|
| Share price | $7.99 | $22.71 |
| Market cap | $430.87M | $443.97M |
| 1-day change | -1.72% | +1.34% |
| YTD return | +0.38% | +8.87% |
| 1-year return | +16.47% | +52.31% |
| 5-year return | +94.88% | -67.37% |
| EPS (TTM) | $-0.72 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $39.53 |
| 52-week low | $5.25 | $15.32 |
| Distance from 52-week high | -23.32% | -42.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.99% | +237.43% |
| Average volume | 175.72K | 219.12K |
| Shares outstanding | 53.93M | 19.55M |
| Employees | 35 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed DMAC by 35.8 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Healthcare · Biotechnology · 60 employees
DMAC vs TECX FAQ
Which is bigger, DiaMedica Therapeutics or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $443.97M compared with $430.87M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or TECX?
TECX returned +52.31% over the past 12 months, compared with +16.47% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.